The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy |
| |
Authors: | Kantarjian Hagop M Bueso-Ramos Carlos E Talpaz Moshe O'Brien Susan Giles Francis Rios Mary Beth Shan Jianqin Cortes Jorge |
| |
Affiliation: | Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. hkantarj@mdanderson.org |
| |
Abstract: | One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-a failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3 - 4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P = 0.45) compared with those with mild?-?moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P = 0.27) and failure-free survival rates (69 vs. 77%; P = 0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |